Document is current
Any future updates will be listed below
-
Authors
Iketani, Sho https://orcid.org/0000-0002-3733-9556
Liu, Lihong
Guo, Yicheng https://orcid.org/0000-0001-5357-660X
Liu, Liyuan
Chan, Jasper F.-W. https://orcid.org/0000-0001-6336-6657
Huang, Yiming
Wang, Maple
Luo, Yang https://orcid.org/0000-0003-3277-8792
Yu, Jian
Chu, Hin https://orcid.org/0000-0003-2855-9837
Chik, Kenn K.-H.
Yuen, Terrence T.-T.
Yin, Michael T.
Sobieszczyk, Magdalena E.
Huang, Yaoxing https://orcid.org/0000-0001-6270-1644
Yuen, Kwok-Yung https://orcid.org/0000-0002-2083-1552
Wang, Harris H. https://orcid.org/0000-0003-2164-4318
Sheng, Zizhang
Ho, David D. https://orcid.org/0000-0003-1627-149X
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation
JPB Foundation
Andrew and Peggy Cherng, Samuel Yin, Carol Ludwig, David and Roger Wu
Health@InnoHK
National Science Foundation (MCB-2032259)
- License Information
-
More Information
Article History
Received: 6 February 2022
Accepted: 28 February 2022
First Online: 3 March 2022
Competing interests
: S.I., Lihong Liu, J.Y., Yaoxing Huang and D.D.H. are inventors on patent applications (WO2021236998) or provisional patent applications (63/271,627) filed by Columbia University for a number of SARS-CoV-2 neutralizing antibodies described in this manuscript. Both sets of applications are under review. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical.
